JP2006527256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006527256A5 JP2006527256A5 JP2006516504A JP2006516504A JP2006527256A5 JP 2006527256 A5 JP2006527256 A5 JP 2006527256A5 JP 2006516504 A JP2006516504 A JP 2006516504A JP 2006516504 A JP2006516504 A JP 2006516504A JP 2006527256 A5 JP2006527256 A5 JP 2006527256A5
- Authority
- JP
- Japan
- Prior art keywords
- atorvastatin
- unit dosage
- dosage form
- excipient
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 17
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 17
- 229960005370 atorvastatin Drugs 0.000 claims 17
- 239000002552 dosage form Substances 0.000 claims 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims 14
- 239000002775 capsule Substances 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008186 active pharmaceutical agent Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000005469 granulation Methods 0.000 claims 2
- 230000003179 granulation Effects 0.000 claims 2
- 239000012535 impurity Substances 0.000 claims 2
- 239000007892 solid unit dosage form Substances 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000003113 alkalizing effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47791803P | 2003-06-12 | 2003-06-12 | |
| PCT/IB2004/001845 WO2004110409A1 (en) | 2003-06-12 | 2004-06-01 | Pharmaceutical compositions comprising atorvastatin manufactured without granulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006527256A JP2006527256A (ja) | 2006-11-30 |
| JP2006527256A5 true JP2006527256A5 (https=) | 2007-08-02 |
Family
ID=33551781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006516504A Pending JP2006527256A (ja) | 2003-06-12 | 2004-06-01 | 造粒することなく製造されたアトルバスタチン含有医薬組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20050271717A1 (https=) |
| EP (2) | EP1977738A1 (https=) |
| JP (1) | JP2006527256A (https=) |
| KR (1) | KR20060028768A (https=) |
| CN (1) | CN100446757C (https=) |
| AR (1) | AR044775A1 (https=) |
| AT (1) | ATE399537T1 (https=) |
| AU (1) | AU2004246866A1 (https=) |
| BR (1) | BRPI0411079A (https=) |
| CA (1) | CA2465621A1 (https=) |
| CO (1) | CO5640072A2 (https=) |
| DE (1) | DE602004014765D1 (https=) |
| DK (1) | DK1635791T3 (https=) |
| ES (1) | ES2305775T3 (https=) |
| MX (1) | MXPA05013392A (https=) |
| NO (1) | NO20055185L (https=) |
| PL (1) | PL1635791T3 (https=) |
| PT (1) | PT1635791E (https=) |
| RU (1) | RU2314804C2 (https=) |
| SI (1) | SI1635791T1 (https=) |
| TW (1) | TW200509905A (https=) |
| WO (1) | WO2004110409A1 (https=) |
| ZA (1) | ZA200509906B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| US7884208B2 (en) * | 2005-10-19 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
| EP1810667A1 (en) * | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| RS52169B (sr) * | 2006-06-12 | 2012-08-31 | Teva Pharmaceutical Industries Limited | Stabilni preparati lakvinimoda |
| WO2008124121A1 (en) * | 2007-04-06 | 2008-10-16 | Scidose, Llc | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
| DE102007052071A1 (de) * | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
| ES2445451T3 (es) | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| WO2009116061A2 (en) * | 2008-01-10 | 2009-09-24 | Alkem Laboratories Ltd. | Stable oral pharmaceutical composition comprising atorvastatin |
| GB0800788D0 (en) * | 2008-01-16 | 2008-02-27 | Glaxo Group Ltd | Niovel formulation |
| CA2637977A1 (en) * | 2008-07-15 | 2010-01-15 | Pharmascience Inc. | Dosage form containing a statin |
| KR20110048571A (ko) * | 2008-09-03 | 2011-05-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제 |
| ME02414B (me) * | 2009-07-30 | 2016-09-20 | Teva Pharma | Tretman kronove bolesti lakvinimodom |
| PT2467372T (pt) * | 2009-08-10 | 2016-08-23 | Teva Pharma | Tratamento de distúrbios relacionados com bdnf usando laquinimod |
| RU2404767C1 (ru) * | 2009-08-11 | 2010-11-27 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма, обладающая гиполипидемической и гипохолестеринемической активностью, и способ ее получения |
| EP2473515A4 (en) | 2009-09-04 | 2013-11-27 | Univ Toledo | PROCESS FOR PREPARING OPTICALLY PURE BETA LACTONS FROM ALDEHYDE AND COMPOSITIONS MADE THEREOF |
| KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
| CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| JP2015535287A (ja) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドのアミン塩 |
| NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| US12083227B2 (en) | 2017-08-18 | 2024-09-10 | Abbvie Inc. | Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis |
| MX2020001877A (es) | 2017-08-18 | 2020-09-14 | Abbvie Inc | Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis. |
| US11980627B2 (en) * | 2019-06-14 | 2024-05-14 | Joshua O. Atiba | Triple pharmaceutical composition for proteinaceous infection |
| EP3982956B1 (en) * | 2019-06-14 | 2024-06-12 | Joshua O. Atiba | Triple pharmaceutical composition for proteinaceous infection |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| ES2133158T3 (es) * | 1993-01-19 | 1999-09-01 | Warner Lambert Co | Formulacion ci-981 oral, estable y proceso de preparacion del mismo. |
| US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| KR100389518B1 (ko) * | 1995-07-17 | 2003-11-15 | 워너-램버트 캄파니 엘엘씨 | 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴) |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| AU3515497A (en) * | 1996-07-29 | 1998-02-20 | Warner-Lambert Company | Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| ES2284219T3 (es) * | 1997-12-19 | 2007-11-01 | Pfizer Ireland Pharmaceuticals | Procedimiento de sintesis de 1,3-dioles. |
| EP1049459B1 (en) * | 1998-01-20 | 2009-04-22 | Applied Analytical Industries, Inc. | Oral liquid compositions |
| SI20109A (sl) | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| IN191236B (https=) | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| HU226640B1 (en) | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
| EP2206497A1 (en) | 1999-11-17 | 2010-07-14 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| EP1274401B2 (en) | 2000-04-10 | 2014-08-13 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| EP1332130A4 (en) | 2000-11-03 | 2004-01-21 | Teva Pharma | HEMICALCIC ATORVASTATIN FORM VII |
| CA2427255A1 (en) | 2000-11-16 | 2002-06-06 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| CA2622477A1 (en) | 2000-12-27 | 2002-07-04 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
| WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| EP1243524A3 (en) | 2001-03-16 | 2004-04-07 | Pfizer Products Inc. | Pharmaceutical kit for oxygen-sensitive drugs |
| EP1241110A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Dispensing unit for oxygen-sensitive drugs |
| IN190564B (https=) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| SK16002003A3 (sk) * | 2001-06-29 | 2004-12-01 | Warner-Lambert Company Llc | Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín) |
| HRP20040077A2 (en) | 2001-07-30 | 2004-06-30 | Reddys Lab Ltd Dr | Crystalline forms vi and vii of atorvastatin-calcium |
| CA2456732C (en) * | 2001-08-07 | 2012-10-30 | Galephar M/F | Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor |
| UA77990C2 (en) | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| BR0307720A (pt) * | 2002-02-14 | 2005-01-25 | Ranbaxi Lab Ltd | Formulações de atorvastatina estabilizadas com adições de metal alcalino, método para produzir uma formulação farmacêutica e estabilizar dita formulação |
| CN100406436C (zh) | 2002-02-15 | 2008-07-30 | 特瓦制药工业有限公司 | 阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法 |
| PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
| AU2002330735A1 (en) | 2002-09-03 | 2004-03-29 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
-
2004
- 2004-04-20 US US10/828,419 patent/US20050271717A1/en not_active Abandoned
- 2004-04-29 CA CA002465621A patent/CA2465621A1/en not_active Abandoned
- 2004-06-01 RU RU2005138496/15A patent/RU2314804C2/ru not_active IP Right Cessation
- 2004-06-01 CN CNB2004800143122A patent/CN100446757C/zh not_active Expired - Fee Related
- 2004-06-01 PL PL04735619T patent/PL1635791T3/pl unknown
- 2004-06-01 SI SI200430802T patent/SI1635791T1/sl unknown
- 2004-06-01 MX MXPA05013392A patent/MXPA05013392A/es unknown
- 2004-06-01 ES ES04735619T patent/ES2305775T3/es not_active Expired - Lifetime
- 2004-06-01 DE DE602004014765T patent/DE602004014765D1/de not_active Revoked
- 2004-06-01 DK DK04735619T patent/DK1635791T3/da active
- 2004-06-01 PT PT04735619T patent/PT1635791E/pt unknown
- 2004-06-01 WO PCT/IB2004/001845 patent/WO2004110409A1/en not_active Ceased
- 2004-06-01 AT AT04735619T patent/ATE399537T1/de not_active IP Right Cessation
- 2004-06-01 BR BRPI0411079-0A patent/BRPI0411079A/pt not_active IP Right Cessation
- 2004-06-01 KR KR1020057023838A patent/KR20060028768A/ko not_active Abandoned
- 2004-06-01 AU AU2004246866A patent/AU2004246866A1/en not_active Abandoned
- 2004-06-01 JP JP2006516504A patent/JP2006527256A/ja active Pending
- 2004-06-01 EP EP08153178A patent/EP1977738A1/en not_active Withdrawn
- 2004-06-01 EP EP04735619A patent/EP1635791B1/en not_active Revoked
- 2004-06-10 AR ARP040102010A patent/AR044775A1/es unknown
- 2004-06-11 TW TW093116996A patent/TW200509905A/zh unknown
-
2005
- 2005-11-04 NO NO20055185A patent/NO20055185L/no not_active Application Discontinuation
- 2005-12-06 ZA ZA200509906A patent/ZA200509906B/en unknown
- 2005-12-12 CO CO05125195A patent/CO5640072A2/es not_active Application Discontinuation
-
2009
- 2009-05-08 US US12/424,972 patent/US20090226510A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006527256A5 (https=) | ||
| RU2005138496A (ru) | Фармацевтические композиции, включающие аторвастатин, изготовленный без гранулирования | |
| JP6545839B2 (ja) | 口腔内崩壊錠及びその製造方法 | |
| RU2153337C2 (ru) | Таблетка парацетамола и домперидона с пленочным покрытием | |
| JP4989733B2 (ja) | 口腔内崩壊錠 | |
| RU2616516C2 (ru) | Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль | |
| WO2008072534A1 (ja) | マンニトール又は乳糖を含有する固形製剤 | |
| CA2601955A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| WO2008072532A1 (ja) | 貯蔵安定性が改善された医薬組成物 | |
| WO2008069262A1 (ja) | 安定性が改善されたフィルムコーティング製剤 | |
| ES2286226T3 (es) | Metodo para fabricar una composicion farmaceutica de baja dosis. | |
| US20070104785A1 (en) | Tablets of linezolid form iii and processes for their preparation | |
| MX2008016568A (es) | Composiciones farmaceuticas de memantina. | |
| CN105338970B (zh) | 包含他达拉非和坦洛新的药物胶囊复合制剂 | |
| CN101791297A (zh) | 阿托伐他汀钙口崩片及其制备方法 | |
| JP2020196713A (ja) | エドキサバンを含有する口腔内崩壊錠 | |
| KR20000075897A (ko) | 파라세타몰을 포함하는 경구용 정제 | |
| CN116490178A (zh) | Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途 | |
| KR20110085307A (ko) | 난용성 약물을 함유하는 경구 제형 | |
| WO2008072533A1 (ja) | 固形製剤の製造方法 | |
| JP6639368B2 (ja) | 糖尿病治療用固形製剤 | |
| CA2566331A1 (en) | Oral delivery system | |
| TWI436760B (zh) | 阿利克侖之蓋崙（ｇａｌｅｎｉｃａｌ）調配物 | |
| KR20150115334A (ko) | 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형 | |
| ES2311230T3 (es) | Composicion farmaceutica que se desintegra oralmente que comprende risperidona. |